



Friday, April 5, 2019 GATEWAY TO THE FUTURE	
Time	Event
5:00-6:30 pm	<b>Opening Ceremony - Why We Are Here</b> [Salon 7-8] Special Video Lisa Rosenbaum Vinita Haroun Lindsey Criswell
6:30-7:30 pm	<b>Welcome Reception</b> [Golden Gate AB & Foyers]

Saturday, April 6, 2019			
Time	Event		
7:30-8:30 am	<b>Breakfast</b> [Golden Gate AB & Foyers]		
7:30 am-5:30 pm	<b>Exhibit</b> [Golden Gate AB] <b>and</b> <b>Poster Hall Open</b> [Golden Gate C]		
8:00-9:00 am	<b>Poster Viewing</b> [Golden Gate C]		
9:00-10:40 am	<b>Plenary 1: Clinical Trials</b> Chair: David Isenberg and Ron van Vollenhoven [Salon 7-8]		
9:00-9:20 am	<i>"Calcineurin Inhibitors in the Management of SLE: An Update"</i> by CC Mok		
9:20-9:40 am	<i>"Combining B Cell Targeted Therapies in SLE"</i> by Onno Teng		
9:40-9:55 am	<b>Abstract 605905:</b> "Efficacy and Safety of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus: Results from the EMBRACE Study" by Jim Oates		
9:55-10:10 am	<b>Abstract 607856:</b> "Ustekinumab Targets a Novel Mechanism of Action to Treat Patients with Systemic Lupus Erythematosus" by Ronald van Vollenhoven		
10:10-10:25 am	<b>Abstract 592301:</b> "IFN $\alpha$ -kinoid in Systemic Lupus Erythematosus (SLE): Results from a Phase 2b, Randomized, Placebo-Controlled Study" by Frédéric Houssiau		
10:25-10:40 am	<b>Abstract 593606:</b> "Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study" by Maria E. Silk		
10:40-11:00 am	<b>Break</b> Golden Gate AB & Foyers		
11:00-12:30 am	<b>© Concurrent Session 1: Pathogenic Mechanisms</b> Chair: Jorge Sanchez Guerrero [Salon 7]	<b>Concurrent Session 1: Clinical Challenges</b> Chair: John Esdaile [Salon 8]	<b>Concurrent Session 1: Quality and Outcome Measures</b> Chair: Paul Fortin [Salon 9]
11:00-11:20 am	<i>"Neutrophils as Pathogenic Players in SLE"</i> by Mariana Kaplan	<i>"Treatment of Hydroxychloroquine-Refractory Cutaneous LE"</i> by Victoria Werth	<i>"Development and Validation of a Low Disease Activity Endpoint for SLE"</i> by Eric Morand
11:20-11:40 am	<i>"Biochemical and Metabolic Control of T cell Function in Lupus"</i> by George Tsokos	<i>"Integrating Molecular Pathways and Clinical Clues to Mend the Heartbreak of Neonatal Lupus"</i> by Jill Buyon	<i>"Remission as SLE Treatment Target in Clinical Practice and in RCTs"</i> by Andrea Doria
11:40-12:00 pm	<i>"Langerhans Cells and Photosensitivity in Lupus"</i> by Theresa Lu	<i>"Adherence to Therapy in Children and Young Adults with Lupus"</i> by Hermine Brunner	<b>Abstract 600280:</b> "SLE Responder Index (SRI) Underestimates Clinical Response in Musculoskeletal Systemic Lupus Erythematosus" by Khaled Mahmoud
12:00-12:15 pm	<b>Abstract 601285:</b> "Lupus Associated Atypical Memory B cells are Abnormally Differentiated with Metabolic Dysregulation and Functional Exhaustion" by Chunmei Wu	<i>"Toward a Clinical Trial in NPSLE"</i> by Betty Diamond	<b>Abstract 605872:</b> "Low Disease Activity State (LDAS) Predicts a Better Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients" by Manuel F. Ugarte-Gil

12:15-12:30 pm	<b>Abstract 606876:</b> "African American SLE Patients with Variable Disease Activity Reveal Alterations in Signaling Pathways and Soluble Mediators that are More Pronounced than European American Patients" by Samantha Slight-Webb	<b>Abstract 599824:</b> "Immunosuppressant Discontinuation in Systemic Lupus Erythematosus: Prevalence, Risk of Subsequent Flare and Effect on Damage Accrual" by Margherita Zen	<b>Abstract 607042:</b> "Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus" by Harrison Lam
12:30-2:15 pm <b>Lunch on own</b>			
12:30-2:15 pm	<b>Patient Luncheon Sponsored by LFA</b> [Salon 10]		
2:15-3:45 pm <b>© Plenary 2: Genetics and Epigenetics</b> Chair: Cristina Lanata [Salon 7-8]			
2:15-2:35 pm	<i>"Sub-phenotype Mapping and Functional Studies to Understand Lupus Genetics"</i> by Tim Niewold		
2:35-2:55 pm	<i>"From Genetics to Genomics: Using Multi-Omic Integrative Analysis to Reclassify Lupus and Other Systemic Autoimmune Diseases"</i> by Marta Alarcon-Riquelme		
2:55-3:15 pm	<i>"Understanding the Contributions of Novel Regulatory Elements in Human Genome to Lupus"</i> by Nan Shen		
3:15-3:30 pm	<b>Abstract 599177:</b> "Targeted Sequencing in 1200 SLE Patients Reveal DAP1 Regulatory Haplotype that Potentiate Autoimmunity" by Prithvi Raj		
3:30-3:45 pm	<b>Abstract 602710:</b> "A Mismatch Repair Genetic Variant is Linked to the Development of Lupus" by Joan Sweasy		
3:45-4:05 pm <b>Break</b> Golden Gate AB & Foyers			
4:05-5:35 pm	<b>Concurrent Session 2: Molecular Targets</b> Chair: Peter Lipsky [Salon 7]	<b>© Concurrent Session 2: Lupus Nephritis</b> Chair: DTM Chan [Salon 8]	<b>PatientSession</b> Clinical Trials and New Treatments for Lupus Co-Chairs: Joan Merrill and Dan Wallace [Salon 9]
4:05-4:25 pm	<i>"Interaction between BAFF and MTX for Inducing Tolerization. A possible Application in Lupus?"</i> by Xavier Mariette	<i>"Molecular Pathology of the Kidney Biopsy in Lupus Nephritis-Clinical Implications"</i> by Brad Rovin	
4:25-4:45 pm	<i>"Rationale for Innovative B cell Targeting"</i> by Thomas Dörner	<i>"Serial Biopsies in Lupus Nephritis: Clinical Implications"</i> by Ana Malvar	
4:45-5:05 pm	<i>"Targetting the Interferon System in Lupus – the Challenges of Selecting the Best Molecule"</i> by Lars Rönnblom	<i>"Mechanisms of Tubulointerstitial Inflammation in Lupus Nephritis"</i> by Marcus Clark	
5:05-5:20 pm	<b>Abstract 606064:</b> "Examining the Transcriptional Impact of Liganded Estrogen Receptor Alpha in the Inflammatory Milieu of Systemic Lupus Erythematosus" by Mara Lennard Richard	<b>Abstract 604195:</b> "Decreased Expression of Renal MiR-127-3p Contributes to the Overactivation of Interferon Signaling Pathway in the Kidney of Lupus Nephritis" by Bo Qu	
5:20-5:35 pm	<b>Abstract 603052:</b> "KZR -616, A Selective Inhibitor of the Immunoproteasome, Attenuates the Development of Murine Lupus" by Tony Muchamuel	<b>Abstract 607051:</b> "Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis" by Cynthia Aranow	

Sunday, April 7, 2019	
Time	Event
7:30-8:30 am	<b>Breakfast</b> [Golden Gate AB & Foyers]
7:30 am-4:00 pm	<b>Exhibit</b> [Golden Gate AB] <b>and</b> <b>Poster Hall Open</b> [Golden Gate C]
8:00-9:00 am	<b>Poster Viewing</b> [Golden Gate C]
9:00-10:20 am	<b>Plenary 3: Precision Medicine</b> Chair: Westley Reeves [Salon 7-8]
9:00-9:20 am	<i>Precision Medicine in SLE: Promise or Propaganda?</i> by Judith James
9:20-9:40 am	SLE Genetics by Timothy Vyse
9:40-10:00 am	<i>"Decoding and Reprogramming Human T Cell Circuitry"</i> by Alex Marson
10:00-10:20 am	<i>"The Microbiome in SLE: Opportunities for Diagnosis and Intervention"</i> by Gregg Silverman

10:20-10:40 am				<b>Break</b> <i>Golden Gate AB &amp; Foyers</i>			
10:40-12:10 am		<b>Concurrent Session 3: Diagnosis and Classification</b> Chair: David Daikh [Salon 7]		<b>Concurrent Session 3: Novel Therapeutic Strategies</b> Chair: William Stohl [Salon 8]		<b>© Concurrent Session 3: Childhood Lupus Around the World</b> Chair: Erica Lawson [Salon 9]	
10:40-11:00 am		<i>"New Classification Criteria for SLE - Reasoning and Results"</i> by Martin Aringer		<i>"Low-dose IL2 Treatment of SLE — a Double Blind, Placebo Controlled Study"</i> by Zhanguo Li		<i>"Childhood onset Lupus: Asian Perspective"</i> by Amita Aggarwal	
11:00-11:20 am		<i>"Using a Novel Approach to Characterizing Lupus Symptoms to Transform Care"</i> by Megan Clowse		<i>"Stem Cell Therapies for Refractory Lupus"</i> by Gary Gilkeson		<i>"cSLE in Africa: Challenging Myths, Confronting Challenges and Seizing Opportunities"</i> by Chris Scott	
11:20-11:40 am		<i>"The ACR Lupus Initiative: Supporting Timely Diagnosis"</i> by Sheryl McCalla		<i>"Mechanism-guided therapy of SLE"</i> by Yoshiya Tanaka		<i>"Neuropsychiatric Manifestations in Childhood-onset SLE"</i> by Simone Appenzeller	
11:40-11:55 am		Abstract 583737: "Phenotypic Subgroups in Systemic Lupus Erythematosus: An Exploratory Cluster Analysis" by Amanda M Eudy		Abstract 605345: "A phase 1b/2a Trial of Tofacitinib, An Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus" by Sarfaraz Hasni		Abstract 58988: "Associated Factors to the Presence of Serious infections in a Large Cohort of Juvenile-onset Systemic Lupus Erythematosus" by Jose Maria Pego Reigosa	
11:55-12:10 pm		Abstract 596599: "Comparison of ACR 1982/1997 and EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in Two Multiethnic Cohorts" by Guillermo J. Pons-Estel		Abstract 605025: "Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment" by Laurence E. Cheng		Abstract 604493: "Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus" by Alaina Davis	
12:30-1:30 pm				<b>Satellite Symposia Lunch - GlaxoSmithKline</b> [Salon 10]			
1:55-3:20 pm		<b>Plenary 4: Precision Medicine: The Accelerating Medicines Partnership</b> Chair: Ward Wakeland [Salon 7-8]				<b>Patient Session</b> Wellnes Workshop by Mariel Dela Paz [Salon 9]	
1:55-2:15 pm		<i>"Novel Cell States in LN Kidney Revealed by Single Cell RNAseq"</i> by Betty Diamond					
2:15-2:35 pm		<i>"Lessons from Rheumatoid Arthritis Applied to SLE: Using Single Cell Genomics to Define the Key Components of Rheumatic Disease"</i> by Soumya Raychaudhuri					
2:35-2:50 pm		Abstract 605011: "The Immune Cell Landscape in Kidneys of Lupus Nephritis Patients" by Celine C. Berthier					
2:50-3:05 pm		Abstract 606913: "Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Type I Interferon Pathway" by Andrea Fava					
3:05-3:20 pm		Abstract 606465: "Insights from Single-cell RNA Sequencing of Skin and Kidney in Lupus Nephritis" by Evan Der					
3:20-3:40 pm				<b>Break</b> <i>Golden Gate AB &amp; Foyers</i>			
3:40-5:10 pm		<b>Concurrent Session 4: Innate Immunity</b> Chair: Keith Elkon [Salon 7]		<b>© Concurrent Session 4: Co-Morbidities</b> Chair: Cynthia Aranow [Salon 8]		<b>Patient Session</b> The Patient Voice Speakers: Gaye Cunnane, Patti Katz, and Kathleen Arntsen [Salon 9]	
3:40-4:00 pm		<i>"Novel innate and adaptive immunity interactions in human SLE"</i> by Virginia Pascual		<i>"Risk Factors for Damage Accrual in SLE: The Role of Race and Ethnicity"</i> by Ashira Blazer			
4:00-4:20 pm		<i>"Interferons and Innate Immunity in Lupus Skin"</i> by Michelle Kahlenberg		<i>"Pediatric SLE Comorbidities"</i> by Aimee Hersh			
4:20-4:40 pm		<i>"Death Begets a New Beginning"</i> by Carla Rothlin		<i>"Predicting Cardiovascular Morbidity in SLE"</i> by Maureen McMahon			
4:40-4:55 pm		Abstract 606175: "Nrf2 Regulation of the Interferon Signature in Lupus Macrophages" by Shuhong Han		Abstract 606728: "Patient Perception of SLE Burden: the Role of Disease Activity, Comorbidities and Treatment" by Elena Elefante			
4:55-5:10 pm		Abstract 593454: "Baricitinib-Associated Changes in Type I Interferon Gene Signature During a 24-Week Phase 2 Clinical SLE Trial" by Thomas Dornier		Abstract 607025: "Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Modified Framingham and Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus" by Jagan Sivakumaran			

**Monday, April 8, 2019**

Time	Event		
7:30-08:30 am	<b>Breakfast</b> [Golden Gate AB & Foyers]		
7:30 am-3:30 pm	<b>Exhibit Open</b> [Golden Gate AB]		
8:00-9:00 am	<b>Special Session</b> [Salon 7-8]		
9:00-10:30 am	<p><b>Plenary 5: Epidemiology/ Outcomes</b> [Salon 7-8]</p> <p><i>Co- Chairs: Ed Yelin and Patti Katz</i></p> <p>9:00-9:20 am <i>"Early Diagnosis of SLE: Where Are We Now?"</i> by Marta Mosca</p> <p>9:20-9:40 am <i>"Does Inflammation Fan the Flames of developing SLE?: The Epidemiologic Evidence"</i> by Karen Costenbader</p> <p>9:40-10:00 am <i>"Should We Use Blood Hydroxychloroquine Levels in SLE Patients?"</i> by Nathalie Costedoat-Chalumeau</p> <p>10:00-10:15 am <b>Abstract 606891:</b> "A High Genetic Risk Score is Associated with Early Disease Onset, Organ Damage and Decreased Survival in Systemic Lupus Erythematosus" by Sarah Reid</p> <p>10:15-10:30 am <b>Abstract 598291:</b> "Impact on the Birth Month in the Development of Systemic Lupus Erythematosus" by Renan Frittoli</p>		
10:30-10:50 am	<b>Break</b> Golden Gate AB & Foyers		
10:50-12:20 pm	<p><b>© Concurrent Session 5: Big Data: Electronic Records, Administrative</b> Chair: Gabriela Schmajuk [Salon 7]</p>	<p><b>Concurrent Session 5: Clinical- Translational Research: Bedside to Bench</b> Chair: Mary Anne Dooley [Salon 8]</p>	<p><b>Concurrent Session 5: Pregnancy/APS</b> Chair: Michelle Petri [Salon 9]</p>
10:50-11:10 am	<i>"Epidemiological Methods in Registry Data: The Swedish Lupus Linkage (SLINK)"</i> by Julia Simard	<i>"Pathways of Antigen Presentation in Autoimmune Disease"</i> by Mark Mamula	<i>"Can We Predict and Prevent Pregnancy Complications in Patients with Lupus and Antiphospholipid Syndrome?"</i> by Jane Salmon
11:10-11:30 am	<i>"ANA in an Academic Medical Center - What It Tells Us About Patients and Doctors"</i> by David Karp	<i>"Outcome Prediction in Lupus Nephritis: from Clinical Parameters to Cellular and Molecular"</i> by Frederic Houssiau	<i>"Lupus Nephritis Before, During, and After Pregnancy"</i> by Savino Sciascia
11:30-11:50 am	<b>Abstract 605090:</b> "Validation of an Administrative Algorithm to Assess SLE Disease Severity" by Cameron B. Speyer	<i>"Using CARRA Consensus Treatment Plans for Comparative Effectiveness Research in Pediatric Lupus"</i> by Emily von Scheven	<i>"Reproductive Health in Women with SLE and APS"</i> by Lisa Sammaritano
11:50-12:05 pm	<b>Abstract 602514:</b> "Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records" by Milena A Gianfrancesco	<b>Abstract 600210:</b> "A Novel CD3/BCMA Bispecific Antibody Selectively Kills Plasma Cells in Bone Marrow of Healthy Individuals with Improved Safety" by Wim van Schooten	<b>Abstract 594559:</b> "Epidemiology of Antiphospholipid Syndrome: A Population-Based Study" by Ali Duarte-Garcia
12:05-12:20 pm	<b>Abstract 606267:</b> "Artificial Intelligence Predicts the Lupus Nephritis Based on Full-phenotype Database with Natural Language Processing Technology" by Ting Li	<b>Abstract 606716:</b> "Immunophenotypic Subgroups of SLE Defined by Autoantibodies, Gene Expression and Flow Cytometric Analysis" by Marta Aguilar Zamora	<b>Abstract 605889:</b> "Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) among Patients with Antiphospholipid Antibodies" by Chack-Yung Yu
12:20-2:05 pm	<b>Lunch on own</b>		

2:05-3:35 pm	<b>Concurrent Session 6: New Technologies</b> Chair: Chaim Putterman [Salon 7]	<b>© Concurrent Session 6: Social and Environmental Determinants of Health</b> Chair: Jinoos Yazdany [Salon 8]	<b>Concurrent Session 6: Pathogenic Mechanisms</b> Chair: Jorge Sanchez Guerrero [Salon 9]	<b>Concurrent Session 6: Patient Program</b> <i>Nutrition and Lifestyle to Improve Health in SLE -what does the evidence show? Integrative Medicine and SLE, an Overview</i> Co-chairs: Sarah Patterson and Sanjay Reddy [Salon 10]
2:05-2:25 pm	"High Dimensional Analyses of T cells in Lupus Nephritis" by Deepak Rao	"Understanding and Addressing Racial/Ethnic disparities in SLE Care and Outcomes" by Candace Feldman	2:05-2:20 Abstract 606818: "Activated Stress Response Genes and Perturbation of Regulatory Pathways in Anti-nuclear Antibody Positive Individuals and SLE Patients Vary by Cell Type and Race in Single-cell Transcriptomic Analyses" by Miles Smith	
2:25-2:45 pm	"Multiplexed Assays for Studying SLE" by PJ Utz	"Social Determinants of Health in the GOAL Cohort" by Sam Lim	2:20-2:35 Abstract 607070: "Immune Pathology Caused by Intrinsic Loss of Control in CD4 T cells" by Jeroen Roose	
2:45-3:05 pm	"Human Immune Census: Population-Scale Single Cell RNA-Sequencing of SLE Patients" by Jimmie Ye	"Environmental Influences on SLE: Lessons Learned from the Gullah Community" by Diane Kamen	2:35-2:50 Abstract 600365: "Disparities of B-cell Type I Interferon Production and Responses in SLE" by W Winn Chatham	
3:05-3:20 pm	Abstract 601625: "Noninvasive Assessment of Experimental Glomerulonephritis Using Fluorescence Molecular Tomography" by Matthew D. Cheung	Abstract 606795: "Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis" by George Stojan	2:50-3:05 Abstract 602713: "The Environment and Lupus: Impact of Inflammation and Diet on T Cell Epigenetics" by Bruce Richardson	
3:20-3:35 pm	Abstract 602725: "MyLupusGuide, a Lupus-specific Web Interactive Navigator, Improves Self-efficacy and Activation in Patients with Low Activation and in Men" by Paul R. Fortin	Abstract 603361: "Racial Disparities in Lupus Medication Adherence" by Kai Sun	2:50-3:05 Abstract 606752: "Transcriptome Analysis of Skin Fibroblasts Derived from Lupus Nephritis Patients Demonstrates Fibrotic and Interferon-related Cellular Biomarkers" by Robert Clancy	
			3:20-3:35 Abstract 607014: "Sequential Blockade of OX40L Followed by PD-1 Altered the Suppressive Function and Proliferation of CD4+ Eegulatory T cells in Lupus Mice" by Maida Wong	
3:35-3:55 pm	<b>Break</b> Ballroom Foyers			
3:55-5:10 pm	<b>© A Bridge to the Future: Reports from Five Continents</b> Chair: Lindsey Criswell [Salon 7-8] Guillermo Pons-Estel (South America) Dzifa Dey (Africa) Savino Sciascia (Europe) Candace Feldman (North America) Nan Shen (Asia)			